EMEA Confirms Positive Benefit-Risk Balance With Raptiva(R) for the Treatment of Psoriasis - European Commission Approved Product Information Update to Include Data on up to Three Years of Treatment With Raptiva(R), the Longest for any Approved Biological Therapy for Psoriasis GENEVA, Switzerland, July 1 /PRNewswire/ -- Merck...
Evidence of Benefit Nearly Halfway Through Weight-Loss Trial WEST PALM BEACH, Fla., June 27 -- When I had a checkup with my primary care physician recently he exclaimed, 'What have you been doing to yourself?You've lost 27 pounds in three months?
How in the world have you done that?' And that's...
A Diabetes Drug Delivery Deal When deciding whether to approve a drug, the FDA only cares whether it's safe and effective.But once the drug hits the market, a third characteristic -- how the drug is taken -- helps determine whether it obtains blockbuster status.
Is Vitamin Deficiency At The Bottom Of Burning Sensation? The People's Pharmacy with Joe and Terry Graedon www.PeoplesPharmacy.com Newspaper Columns, Pharmacy Q&A June 20, 2008 Q.Can you help me?
Ive had a burning sensation on my tongue and the soles of my feet for weeks?
Ive tried...
Sanofi-Aventis plans rival bid for Czech generic drugmaker Zentiva (RTTNews) - French drugmaker Sanofi-Aventis (SNY) said Wednesday that it plans to offer CZK 1,050 per share for the 75.1% of Czech generic drugmaker Zentiva it does not already own, topping a rival bid of CZK 950 per share from Czech...
Sanofi-Aventis plans rival bid for Zentiva (RTTNews) - French drugmaker Sanofi-Aventis (SNY: News, Chart, Quote ) said Wednesday that it plans to offer CZK 1,050 per share for the 75.1% of Czech generic drugmaker Zentiva it does not already own, topping a rival bid of CZK 950 per...
Sanofi-Aventis plans rival bid for Czech generic drugmaker Zentiva (RTTNews) - French drugmaker Sanofi-Aventis (SNY | Quote | Chart | News | PowerRating) said Wednesday that it plans to offer CZK 1,050 per share for the 75.1% of Czech generic drugmaker Zentiva it does not already own, topping a rival bid of...
Merck Serono and Bionomics Announce Multiple Sclerosis Development and Licensing Agreement - Bionomics and Merck Serono to Collaborate to Discover and Develop Novel, Oral Treatment for MS - Collaboration Based on Novel Compounds That Allow Selective Inhibition of The Immune Cells Which Cause Nerve Cell Damage in Patients With MS...
Viewpoint: Should a pharmacist admit fault after a dispensing error? Some industry leaders have recommended that we should immediately fess up after we make a drug error.Let me make the case why I don't think the issue is quite that simple.
I happened to be visiting my stepfather when he noticed that...
ASCO: Diabetes Drug Shows Potential as Breast Cancer Treatment Aid Bloom with Breastcancer.org this spring by supporting the care until the cure.Learn more What breastcancer.org says about this article Sometimes breast cancer is treated with chemotherapy BEFORE surgery to help shrink the cancer before it's...
Merck Strengthens Its Prescription Medicines Portfolio in Latin America Merck Serono to commercialize portfolio of established pharmaceutical medicines from Bristol-Myers Squibb in Latin America DARMSTADT, June 10, 2008 Merck KGaA announced today that its Merck Serono division signed a distribution agreement...
Novo pushes for early use of insulin Novo Nordisk is using its clout as the world's biggest maker of in sulin to promote early use of the product, potentially reversing decades of medical practice in treating diabetes.Almost twice as many patients diagnosed with the most...
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus - Trial in Systemic Lupus Erythematosus (SLE) Intended to Form Part of Potential Registration Package GENEVA, Switzerland, June 5 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its development partner...
Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer - New Data Provides the Basis for the Future Role of Erbitux (cetuximab) as a Standard in Combination With Platinum-Based Chemotherapy in the 1st-Line Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) - Location: Annual Meeting...
Nigerian counterfeit drug seizure KEYWORDS GET THE LATEST MARKET REPORTS All market reports 29-May-2008 - A 20ft container of counterfeit pharmaceuticals has been impounded by the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC).The drugs...
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva in the Treatment of Psoriasis Pu Longest continuous-treatment prospective study of a biological therapy for psoriasis GENEVA, Switzerland, May 5, 2008 Final results of the first three-year prospective efficacy and safety study in moderate-to-severe chronic plaque psoriasis...
